Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/qWUwrAcCJZ https://t.co/6S7Y6p7BnF

Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18  vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o

Anakinra in COVID showed mixed (often negative) results. But this Turkish retrospective observational study comparing standard of care to IV anakinra in severe COVID pts. IV ANAK had less thromboembolic event (5% vs 12.3%, p = 0.038), better survival https://t.co/4webWJKEfB https://t.co/85GnCd6N8O

Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/1Yg40HPTzh https://t.co/NqCwEzmZ1g

Kaiser/California EHR study of #SLE pregnancies (2011-2020) - 657 pregnancies in 453 prs; The live birth rate = 74%, 23% w/ Spontaneous Ab, 2% ectopic/molar & <1% stillbirths. Variable outcomes by race & ethnicity, aPL status & nephritis history https://t.co/gvmYpTuFon https://t.co/9TeG8kfLmK

JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits - Dx algorithm - Pathophys - Rx options - Alternative Rx https://t.co/4sd2HqUX9Y https://t.co/FoVHFnfEPa

Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp

Hypertension not associated with High NSAID Doses in AxSpA At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs. https://t.co/UsRfobVHO7 https://t.co/fGj5yO53Yk

Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/vEQUZGAuJe

2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/xPXUd9vHyE https://t.co/uESOGYhAdw